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E D I T O R I A L
Blueprint for mechanistic, data-rich early phase clinical
pharmacology studies in dermatology
Numerous new and innovative drugs are currently entering the der-
matological market space. The dermatologist of the 20th century
used to have a limited amount of pharmacological treatment options
comprising mainly nonspecific drugs such as (topical) corticosteroids
and methotrexate. This has changed tremendously in the last two
decades when novel, targeted therapies became the new hallmark
for the treatment of moderate to severe skin diseases.
Risankizumab, for instance, is a monoclonal antibody selectively
targeting interleukin 23 in chronic plaque psoriasis and is the 12th
unique biologic drug that is registered in Europe and in the United
States. Having these multiple, targeted treatment options available
has greatly improved the flexibility and personalization of psoriasis
care in clinical practice. However, such targeted treatment options
are still under development for various other indications including
atopic dermatitis, chronic urticaria, hidradenitis suppurativa, vitiligo,
and alopecia areata.
By definition, the early exploratory phase in clinical drug devel-
opment is performed without clinical information on the drug,
e.g., unknown active dose, unclear regimen, and uncertain pharma-
cological activity. This uncertainty leads to a probability of success
as low as 13.8% from phase 1 to market registration across all
therapeutic areas and 6.3% for auto-immune/inflammation treat-
ments in particular.1 Therefore, more rational approaches for drug
development are needed such as question-based drug development
with biomarkers included2 or the quantitative model-based
approach.2 However, there is no clear guidance on how to perform
early phase clinical trials with innovative topical or systemic drugs
at the cross-road of dermatology and clinical pharmacology. Hence,
with this editorial, we aim to illustrate the various aspects of recent
examples to enable rational dermatological drug development for
mostly nonmalignant skin diseases in the early clinical phase,
i.e., human pharmacology and exploratory therapeutic setting.
Importantly, biomarkers and drug development tools described in
this manuscript need to be qualified or validated to enable reliabil-
ity of the observations as described in more detail in the FDA
guidances.3,4
1 | CORNERSTONE: PHARMACOKINETIC
PROPERTIES
One of the main aims in early phase clinical pharmacology studies is
to explore the pharmacokinetic (PK) properties of the new drug.
While PK profiling is rather easy for systemic compounds, it is more
complicated for topical drugs, because of the investigation of drug
concentrations in skin. Profiling of dermal PK poses an immense
challenge for clinical pharmacologists, both for the topical and sys-
temic route of administration. However, major advancements have
been made using methods including microdialysis5 and the more
recent open-flow microperfusion.6 Lately, the FDA has officially rec-
ognized the latter technique as a valuable tool to evaluate dermal PK
of new drugs.7 In addition, more invasive techniques comprise mass
spectrometry-based imaging from skin punch biopsies. The latter
triggers more attention since matrix-assisted laser desorption
ionization-time-of-flight (MALDI-TOF) imaging techniques have
become more established, enabling profiling of quantitative skin dis-
tribution.8 An interesting alternative for dermal PK assessments is
the noninvasive confocal Raman spectroscopy whereby the first vali-
dation results hold promise to wider application and quantification
in vivo.9,10 We should also note the rapidly expanding field of mini-
mally invasive techniques for systemic PK profiling, including the
only recently reported dry blood spot analysis for biologics
(e.g., infliximab and adalimumab).11,12 While the most suitable tech-
nique needs to be selected on a case-by-case basis, the growing
number of technical possibilities is encouraging, enabling the more
precise assessment of dermal pharmacokinetics in future human
pharmacology studies.
2 | CORNERSTONE: PHARMACODYNAMIC
PROPERTIES
Next to PK and safety/tolerability profiling, early phase clinical
pharmacology studies also should include the evaluation of
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pharmacodynamic effects of a new drug, as was recently re-
emphasized by the EMA guidance on first-in-human clinical trials.13
Pharmacodynamic properties can be investigated at the level of
receptor occupancy in the target tissue and engagement of the tar-
get, assessed by proximal or distal functional downstream bio-
markers to monitor target modulation.14 Given the fact that most
dermatological drugs have an immunomodulatory mechanism of
action, translational models are of particular interest for human
pharmacology. Such studies include in vivo or ex vivo immune
challenges targeting innate immunity pathways,
e.g., lipopolysaccharide for Toll-like receptor (TLR)-4 and imiquimod
for TLR-7 stimulation, or adaptive pathways, e.g., the neoantigen
keyhole limpet hemocyanin driving an antigen-specific T-cell and B-
cell response.15,16 Other valuable models include histamine or cap-
saicin challenges via skin prick, as model for pruritus as was
reviewed by Assil et al.17 Combining a dose-ranging trial with a
proof-of-pharmacology trial at the earliest clinical stage (i.e., in
healthy volunteers) results in proving the pharmacological action
and supports rational dose selection for a subsequent “proof-of-
concept” trial in a relevant patient population. Of note, for topical
drugs, the healthy volunteer part can often be minimized or omit-
ted, and the assessments can be performed directly in the relevant
patient population. This approach can be more advantageous since
it enables direct investigations in presence of disease pathology in
a “first-on-human” study. Proven examples are the psoriasis plaque
test18 and the micro-zone models for atopic dermatitis19 whereby
pharmacological properties could be explored in parallel with clini-
cal efficacy of the drug.
3 | CORNERSTONE: SENSITIVE AND
OBJECTIVE CLINICAL ENDPOINTS
In pivotal dermatology trials, physician-evaluated scores play a key
role in the assessment of drug efficacy. These symptom-grading
scales, such as the Investigator Global Assessment (IGA) or Physician
Global Assessment (PGA), can give a crude estimation of the disease
“severity” and potential improvement during the clinical trial. These
assessments are routinely performed and standardized, as is explicitly
demanded by the regulatory agencies. However, their obvious disad-
vantages are (i) limited objectivity since the physician performing the
assessment might introduce a response quantification bias,
(ii) potential inter-rater variability, and (iii) lack of sensitivity that is
needed to quantify smaller effects of a novel drug which are highly
likely to occur in early phase clinical studies. Therefore, more objec-
tive endpoints are needed to support unbiased objective evaluation of
drug efficacy. The amount novel techniques have expanded, providing
many new endpoints currently postulated as value-based endpoints.20
For example, in the evaluation of new drugs for the treatment of
chronic plaque psoriasis, the PGA along with the Psoriasis Area Sever-
ity Index (PASI) are currently the gold standard assessments. Novel
imaging techniques now additionally provide the digital PASI21 as well
as objective image quantification of an inflammatory skin lesion using
Laser Speckle Contrast Imaging.16 By measuring the perfusion of the
lesion, the latter technique can objectively measure the inflammatory
status of a psoriasis plaque and thereby potential drug effects. For
other skin diseases including hidradenitis suppurativa mobile and
automated tools are available to determine erythema.22 To assess
F IGURE 1 Sytems dermatology profiling of disease and drug effects needs a multi-modal approach with different technologies. BSA, body
surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; MALDI-TOF MS, matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry; oSCORAD, objective scoring atopic dermatitis; NRS, numerical rating score; PASI,
psoriasis area and severity index; UAS7, urticaria activity score; UCT, urticaria control test; VAS, visual analogue scale
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disease severity more objectively in atopic dermatitis the digital
eczema area and severity index (EASIdig) demonstrated good correla-
tion to clinical scores23 and even more accurate assessments using
artificial intelligence are currently being developed. Alternatively, the
use of a combination of serum biomarkers may be a more objective
tool for the assessment of clinical scores and drug effects in patients
with atopic dermatitis.24 For (benign) skin neoplasia such as cutaneous
warts, three-dimensional (3D) imaging offers the opportunity to both
accurately and precisely quantify lesions in terms of planimetry as well
as high-resolution photo documentation25 next to the morphological
clinical assessment.26 All imaging and biomarker techniques illustrate
a more objective approach supporting well-informed decision-making
during the process of drug development.
4 | CORNERSTONE: INTEGRATED,
MULTIMODAL PROFILING OF DISEASE AND
DRUG EFFECTS
The technological revolution of the last 20 years has had a major
impact on clinical research. A rapidly growing list of tools is currently
available for the comprehensive characterization of drug effects in the
individual patient. Tools can be classified into different domains,
including patient-reported outcomes, the classical physician-based
clinical scoring, and biophysical, cellular, and molecular biological bio-
markers as well as (pharmaco)genomics and the external exposome.
Various techniques can be employed, including transcriptomics, prote-
omics, lipidomics, and metabolomics as well as microbiomics (recently
reviewed in Niemeyer-van der Kolk et al.27 for dermatological drug
development). By integrating this data from different domains,
assessed by multiple techniques, we follow a so-called “systems der-
matology” approach, describing the pathophysiology in high detail and
supporting a holistic view on skin disease and drug effects (Figure 1).
As a consequence, response or nonresponse to drugs can be eluci-
dated and explained in more mechanistic detail. Finally, integration is
needed of the holistic construct of the individual patient and real-
world data captured at home for different symptoms such as itch,
sleeplessness, and erythema as well as monitoring and controlling of
treatment adherence. Recently, a meta-analysis of data from 6 differ-
ent trials with topical drug application in 258 participating patients for
various dermatological indications showed a mean treatment adher-
ence of 98%, which is encouraging.28 A noteworthy addition to this is
the deep phenotyping of patients, often conducted in an observa-
tional study design prior to a clinical trial to characterize the disease,
patient population, biomarkers, and associated endpoints most suit-
able to target.
5 | CORNERSTONE: LANDSCAPE FOR
TRIAL CONDUCT: COLLABORATIONS
A “catalyzing” landscape for clinical trials is an essential extrinsic factor
needed for efficient drug research, in addition to earlier described four
cornerstones on “intrinsic clinical trial factors.” Due to the complexity
of modern clinical trials, a multidisciplinary setup is required involving
various specialists such as technicians, bioinformaticians, dermatolo-
gists, key opinion leaders, and research physicians. All specialists and
patients need to collaborate seamlessly while trial infrastructure and
all associated procedures are fully aligned according to the standards
of Good Clinical Practice. The most important critical aspect remains
the efficient and effective identification and recruitment of suitable
patients in clinical trials, which requires strong collaborative efforts
and teamwork within the dermatological community. For this reason,
active communities have been formalized in two different European
countries: the UK Dermatology Clinical Trial Network (UKDCTN)29
and the Dutch Clinical Network for Trials in Dermatology, called
CONNECTED.30 Through trial prioritization and complementary activ-
ities, these networks will flourish in trial execution, which has mutual
benefits for each participating site and their patients. As for the Dutch
CONNECTED network, physicians can provide input about study
design, refer potentially eligible patients, and have timely access to
the results of recently completed studies. Through multicenter recruit-
ment, also mid-size proof-of-concept trials can be performed in a sin-
gle center with up to 46 patients with moderate to severe psoriasis31
or 80 patients with cutaneous warts in a timely manner.32 Obvious
advantages are the centralization of logistics, large samples sizes,
high-data quality, and consistency as well as lower costs for the
startup of one study site (versus multiple sites). Hence, this single-
center approach with multisite recruitment marks the way-to-go for
efficient and method-rich early clinical trials in the future.
In summary, these five cornerstones describe the most important
aspects of a blueprint for early phase clinical pharmacology studies in
the field of clinical pharmacodermatology. Each new drug needs a
new tailored approach towards drug development. Taking into
account the mentioned aspects will increase the probability that
undesired drug features (in terms of safety, pharmacokinetics, or phar-
macodynamics) are detected early in the clinical development process
and mitigate the risk of drug failing in pivotal trials.
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